HRT Financial’s Summit Therapeutics SMMT Stock Holding History

HRT Financial’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-241,685	Closed	-$5.14M	–	3595
2025 Q2	$5.14M	Buy	+241,685	New	+$5.51M	0.02%	529
2023 Q2	–	Sell	-397,903	Closed	-$696K	–	3211
2023 Q1	$696K	Buy	397,903 +359,477	+936%	+$980K	0.01%	1164
2022 Q4	$163K	Buy	+38,426	New	+$69.9K	﹤0.01%	1982
2021 Q2	–	Sell	-29,906	Closed	-$175K	–	3471
2021 Q1	$175K	Buy	+29,906	New	+$193K	﹤0.01%	2347
2020 Q4	–	Sell	-18,119	Closed	-$62K	–	2409
2020 Q3	$62K	Buy	+18,119	New	+$62.7K	﹤0.01%	1630

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

ACL

APEIRON Capital Ltd Hong Kong $107M AUM 9.59% 1-Year Est. Return

HRT Financial's SMMT Position: Q3 2025 in Review

HRT Financial sold out of Summit Therapeutics (SMMT) in Q3 2025, closing a stake of 241,685 shares — an estimated $5.14M sold.

HRT Financial first reported a position in SMMT in Q3 2020 and held it in 5 quarters. The position peaked at $5.14M in Q2 2025. 232 funds tracked by Wall St. Rank hold SMMT as of Q3 2025.

HRT Financial reported no remaining Summit Therapeutics position as of Q3 2025 after selling out during the quarter.
HRT Financial sold 241,685 Summit Therapeutics shares in Q3 2025, an estimated $5.14M.
HRT Financial first reported a position in Summit Therapeutics in Q3 2020 and held it in 5 quarters.
HRT Financial's Summit Therapeutics position peaked at $5.14M in Q2 2025.
232 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2025.

Based on HRT Financial's 13F filing for Q3 2025, filed 14 Nov 2025.